product
Intellicyt® T Cell Activation Cell and Cytokine Profiling Kit
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
List view / Grid view
cytokines
article
Expert view: GMP proteins for therapeutic manufacturing: combining consistency, safety, and supply
Cell therapies offer revolutionary new approaches for treating humandisease. Most of these treatments use GMP cytokines and growthfactors for the differentiation, expansion, and maintenance of cells.It is critical that GMP protein suppliers offer the optimal combinationof consistency, safety, and stable supply chain.
article
Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments
Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.
news
C6 gene unlocks mysteries to our immunity
Researchers have identified a new gene that plays a critical role in regulating the body's immune response to infection and disease...
news
Study provides insight into blood signatures of inflammation
A new study has identified a pattern of inflammation associated with cardio-metabolic risks...
article
Expert view: Addressing the big challenges in cell-based assays
As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
news
Blocking 20-HETE chemical counters the siren call of aggressive cancers
Scientists have successfully blocked the powerful call of two types of aggressive cancer – glioblastoma and breast cancer – in laboratory models; with evidence that inhibiting the chemical 20-HETE halts tumour growth.
whitepaper
Application note: High throughput quantitation of cytokine biomarkers using LANCE Ultra TR-FRET assays
In this application note, PerkinElmer demonstrates the sensitivity, robust performance, and HTS suitability of the LANCE Ultra cytokine biomarker kits.
whitepaper
Application note: Multiplexed detection of mouse cytokines using QBeads and the iQue Screener
This application note illustrates the value of multiplexing, rapid sampling, and assay miniaturisation using QBeads on the iQue Screener...
webinar
Evaluating immunotherapeutic approaches with large scale functional assays for immuno-oncology
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
news
Cytokine molecules unearth development of progressive MS
Scientists have uncovered two closely related cytokines molecules involved in cell communication that explain why some people develop progressive MS...
whitepaper
Application note: Application of MultiCyt QBeads for high throughput cytokine profiling in human peripheral blood mononuclear cells
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
news
IL-34: a new target to tackle chemo-resistant cancer cells
3 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers found that A549-DR was resistant to the chemotherapeutic drug when transplanted in mice, while A549-DR with depleted IL-34 became sensitive...
article
Immune checkpoint inhibitors: targets on the horizon
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...